Business
Annual Financial Report
BSF Enterprise PLC has published its Annual Report and Consolidated Financial Statements for the year ended 30 September 2025, detailing significant commercial and technical progress across its subsidiaries. The company reported a reduced net loss of £1,013,527, down from £1,672,291 in the prior year, attributed to cost control and increased grant income. Key developments include the launch of CytoBoost™ and expansion of City-Mix™, a major breakthrough with 2mm-thick scaffold-free leather, and a licensing agreement for liquid cornea technology. Strategic fundraising initiatives, including shareholder approval for up to £15 million via warrants, are in place to support commercialisation, expansion, and potential acquisitions. Disclaimer*
About this update from Bsf Enterprise Plc
[{"type":"text","content":"\n\n30 January 2026\n\nBSF Enterprise PLC\n(\"BSF\" or the \"Company\")\nPublication of Annual Report and Accounts\n \nBSF Enterprise PLC (LSE: BSFA), a leading innovator in tissue-engineered materials, is pleased to announce that its Annual Report and Consolidated Financial Statements for the year ended 30 September 2025 have been published.\n \nThe Annual Report is now available to view on the Company's website at: https://bsfenterprise.com/reports-documents-and-presentations#reports\n \nIn accordance with Listing Rule requirements, copies of the Annual Report will be submitted to the National Storage Mechanism and will shortly be available for inspection.\n \nHighlights from the period include:\n \n· Significant commercial and technical progress across core subsidiaries: 3D Bio-Tissues Limited (3DBT), Lab-Grown Leather Limited (LGL), and Kerato Limited\n \n· Launch of CytoBoost™ bioactive media additive and continued expansion of City-Mix™ for cost-effective cultivated meat production\n \n· Major breakthrough with the world's first 2mm-thick scaffold-free leather; ongoing collaborations with luxury fashion brands and advancement toward commercial production of T-Rex derived leather product\n \n· Key licensing agreement secured with the University of Montreal for liquid cornea technology, supporting in-situ corneal repair; veterinary clinical trials planned for 2026 and human trials in 2027\n \n· Strategic fundraising initiatives, including shareholder approval for up to £15 million via warrants, to support commercialisation, spin-outs, Greater China expansion, and potential acquisitions\n \n· Reduced net loss to £1,013,527 (2024: £1,672,291) reflecting careful cost control and increased grant income\n \nEngage with the BSF Enterprise management team directly by asking questions, watching video summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor website here:\n \nFor further enquiries, please visit www.bsfenterprise.com or contact:\n \n\n\n\n\nBSF Enterprise PLC\nGeoff Baker - Chairman\nChe Connon - CEO & Director\n \nWe encourage all ...